Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
patient decrease » point decrease (Expand Search), transient decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
c largest » _ largest (Expand Search), c large (Expand Search)
_ patient » _ patients (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
patient decrease » point decrease (Expand Search), transient decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
c largest » _ largest (Expand Search), c large (Expand Search)
_ patient » _ patients (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
10
-
11
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
12
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
13
-
14
-
15
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
16
-
17
-
18
-
19
-
20